ForePass Replicates Bariatric Surgery Effects with Superior Results
Keyron announced that its ForePass endoscopic metabolic bypass platform has been shown to replicate insulin sensitivity levels seen after biliopancreatic diversion while outperforming semaglutide (Ozempic/Wegovy) in weight control, according to a recent study published in the journal Gut.
LONDON & ROME–(BUSINESS WIRE)–Keyron today announced publication in Gut, the highest-ranked gastroenterology journal globally (Impact Factor: 26.2), demonstrating that its ForePass endoscopic metabolic bypass platform reproduced insulin sensitivity levels observed following biliopancreatic diversion (BPD) while substantially outperforming semaglutide (Ozempic/Wegovy) in weight control in a randomized preclinical study. Widely regarded as the most metabolically effective and invasive bariatric